Comparative in-vitro activity of levofloxacin, other fluoroquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue SUPPL. C, 1999, Pages 33-36

  Ullmann, U ^a   Schubert, S ^a   Krausse, R ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DOXYCYCLINE; ERYTHROMYCIN; FLEROXACIN; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; CONFERENCE PAPER; CONTROLLED STUDY; DILUTION; GENITAL TRACT INFECTION; GRAM NEGATIVE INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA HOMINIS; UREAPLASMA UREALYTICUM;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; DOXYCYCLINE; ERYTHROMYCIN; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOPLASMA HOMINIS; OFLOXACIN; UREAPLASMA UREALYTICUM;

EID: 0033049341     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/43.suppl_3.33     Document Type: Conference Paper

References (38)

1. Taylor-Robinson, D. & Munday, P. E. (1988). Mycoplasmal infection of the female genital tract and its complications. In Genital Tract Infection in Women, (Hare, M. J., Ed.), pp. 228-47. Churchill Livingstone, Edinburgh, UK.
2. Taylor-Robinson, D. & McCormack, W. M. (1980). The genital mycoplasmas. New England Journal of Medicine 302, 1003-10/1063-7.
3. Taylor-Robinson, D. (1989). Genital mycoplasma infections. Clinics in Laboratory Medicine 9, 501-23.
4. Taylor-Robinson, D. (1995). Mycoplasma and Ureaplasma. In Manual of Clinical Microbiology, 6th Edition, (Murray, P. R., Baron, E. J., Pfaller, M. A., Tenover, F. C. & Yolken, R. H., Eds), pp. 652-62. ASM Press, Washington, DC.
5. Mardh, P. A. (1983). Mycoplasma hominis. A neglected human pathogen. European Journal of Clinical Microbiology 2, 303-8.
6. Krausse, R., Kühne, H.-H. & Ullmann, U. (1987). Die isolierung von mykoplasmen und chlamydien bei patienten mit urogenitalinfektionen. Immunity and Infections 15, 112-9.
7. Plummer, D. C., Garland, S. M. & Gilbert, G. L. (1987). Bacteraemia and pelvic infection in women due to Ureaplasma urealyticum and Mycoplasma hominis. Medical Journal of Australia 146, 135-7.
8. Phillips, I., Dimian, C., Barlow, D., Moi, H., Stolz, E., Weiner, W. et al. (1996). A comparative study of two different regimens of sparfloxacin versus doxycycline in the treatment of non-gonococcal urethritis in men. Journal of Antimicrobial Chemotherapy 37, Suppl. A, 123-4.
9. Simon, C. & Stille, W. (1997). Antibiotika-Therapie in Klinik und Praxis, 9. Aufl. Schattauer, Stuttgart/New York.
10. Roberts, M. C., Koutsky, L A., Holmes, K. K., LeBlanc, D. J. & Kenny, G. E. (1985). Tetracycline-resistant Mycoplasma hominis strains contain streptococcal tetM sequences. Antimicrobial Agents and Chemotherapy 28, 141-3.
11. Roberts, M. C. & Kenny, G. E. (1986). Dissemination of the tetM tetracycline resistance determinant to Ureaplasma urealyticum. Antimicrobial Agents and Chemotherapy 29, 350-2.
12. Leng, Z., Riley, D. E., Berger, R. E., Krieger, J. N., Roberts, M. C. (1997). Distribution and mobility of the tetracycline resistance determinant tetQ. Journal of Antimicrobial Chemotherapy 40, 551-9.
13. Stein, G. E. (1996). Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clinical Infectious Diseases 23, Suppl. 1, S19-24.
14. Kenny, G. E., Hooton, T. M., Roberts, M. C., Cartwright, F. D. & Hoyt, J. (1989). Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method. Antimicrobial Agents and Chemotherapy 33, 103-7.
15. Leroy, O., Beuscart, C., Chidiac, C., Sivery, B., Senneville, E., Vincent du Laurier, M. et al. (1989). Therapy of pneumonias due to Legionella, Mycoplasma, Chlamydiae and Rickettsia using olloxacin. Pathologie Biologie 37, 1137-40.
16. Kikuchi, N., Kawashima, T. & Onozaki, I. (1990). Clinical evaluations of ofloxacin in the treatment of Mycoplasma pneumoniae pneumonia in adults. Japanese Journal of Antibiotics 43, 100-4.
17. Moller, B. R., Herrmann, B., Ibsen, H. H., Halkier-Sorensen, L., From, E. & Mardh, P. A. (1990). Occurrence of Ureaplasma urealyticum and Mycoplasma hominis in non-gonococcal urethritis before and after treatment in a double-blind trial of ofloxacin versus erythromycin. Scandinavian Journal of Infectious Diseases 68, Suppl., 31-4.
18. Arai, S., Gohara, Y., Kuwano, K. & Kawashima, T. (1992). Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae. Antimicrobial Agents and Chemotherapy 36, 1322-4.
19. Kenny, G. E. & Cartwright, F. D. (1993). Effect of pH, inoculum size, and incubation time on the susceptibility of Ureaplasma urealyticum to erythromycin in vitro. Clinical Infectious Diseases 17, Suppl. 1, 3215-8.
20. Black, F. T. (1973). Modification of the growth-inhibition test and its application to human T-mycoplasmas. Applied Microbiology 25, 528-33.
21. Shepard, M. C. & Lunceford, C. D. (1976). Differential agar medium (A7) for identification of Ureaplasma urealyticum (human T mycoplasmas) in primary cultures of clinical material. Journal of Clinical Microbiology 3, 613-25.
22. Davis, R. & Bryson, H. M. (1994). Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 47, 677-700.
23. Balfour, J. A., Todd, P. A. & Peters, D. H. (1995). Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections. Drugs 49, 794-850.
24. Davis, R., Markham, A. & Balfour, J. A. (1996). Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 51, 1019-74.
25. Kenny, G. E. & Cartwright, F. D. (1993). Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116. Antimicrobial Agents and Chemotherapy 37, 1726-7.
26. Kenny, G. E. & Cartwright, F. D. (1996). Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Antimicrobial Agents and Chemotherapy 40, 1048-9.
27. Perea, E. J., Aznar, J., Garcia-Iglesias, M. C. & Pascual, A. (1996). Comparative in-vitro activity of sparfloxacin against genital pathogens. Journal of Antimicrobial Chemotherapy 37, Suppl. A, 19-25.
28. Kenny, G. E. & Cartwright, F. D. (1991). Susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum to two new quinolones, sparfloxacin and WIN 57273. Antimicrobial Agents and Chemotherapy 35, 1515-6.
29. Furneri, P. M., Bisignano, G., Cerniglia, G., Nicoletti, G., Cesana, M. & Tempera, G. (1994). In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922. Antimicrobial Agents and Chemotherapy 38, 2651-4.
30. Felmingham, D., Robbins, M. J., Ingley, K., Mathias, I., Bhogal, H., Leakey, A. et al. (1997). In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. Journal of Antimicrobial Chemotherapy 39, Suppl. B, 43-9.
31. Krausse, R. & Ullmann, U. (1990). Die wirkung von makrolidantibiotika gegenüber Mycoplasma hominis, Ureaplasma urealyticum und Chlamydia trachomatis. Fortschritte der Antimikrobiellen u. Antineoplastischen Chemotherapie 9-1, 55-63.
32. Krausse, R. & Ullmann, U. (1968). Comparative in vitro activity of fleroxacin (RO 23-6240) against Ureaplasma urealyticum and Mycoplasma hominis. European Journal of Clinical Microbiology and Infectious Diseases 7, 67-9.
33. Waites, K. B., Duffy, L. B., Schmid, T., Crabb, D., Pate, M. S. & Cassell, G. H. (1991). In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to sparfloxacin and PD 127391. Antimicrobial Agents and Chemotherapy 35, 1181-5.
34. Cohen, M. A. & Huband, M. D. (1997). In-vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to clinafloxacin, PD131628, ciprofloxacin and comparator drugs. Journal of Antimicrobial Chemotherapy 40, 308-9.
35. Matlow, A., Th'ng, C., Kovach, D., Quinn, P., Dunn, M. & Wang, E. (1998). Susceptibilities of neonatal respiratory isolates of Ureaplasma urealyticum to antimicrobial agents. Antimicrobial Agents and Chemotherapy 42, 1290-2.
36. Bébéar, C. M., Renaudin, H., Boudjadja, A. & Bébéar, C. (1998). In vitro activity of BAY 12-8039, a new fluoroquinolone, against mycoplasmas. Antimicrobial Agents and Chemotherapy 42, 703-4.
37. Lefèvre, J. C., Bauriaud, R., Gaubert, E., Escaffre, M. C. & Lareng, M. B. (1992). In vitro activity of sparfloxacin and other antimicrobial agents against genital pathogens. Chemotherapy 38, 303-7.
38. Chien, S. C., Rogge, M. C., Gisclon, L. G., Curtin, C., Wong, F., Natarajan, J. et al. (1997). Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrobial Agents and Chemotherapy 41, 2256-60.